secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0000950170-24-029221
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema reports FY2023 net loss $96.7M, cash $261.8M; palazestrant Phase 3 underway
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $261.8M as of Dec 31, 2023; net loss $96.7M for FY2023 vs $104.8M in FY2022.
- GAAP R&D expenses $86.1M in FY2023 (including $11.8M stock-based comp); non-GAAP R&D $74.4M.
- Pivotal Phase 3 OPERA-01 monotherapy trial initiated Q4 2023; top-line results expected in 2026.
- Phase 2 study of palazestrant + ribociclib (60 patients) fully enrolled; data at ESMO Breast Cancer May 2024.
- KAT6 inhibitor OP-3136 nominated as development candidate; IND filing expected late 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000095017024029221/0000950170-24-029221-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000095017024029221/olma-20240311.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-029221

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer